RxSight, Inc.
RXST · XNASCIK 1111485fmd_1EK5ZJEFRJA416Y695FSM14GMCManufacturing · Ophthalmic GoodsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 15 | 23 | 49 | 89 | 140 | 134 |
| Cost of revenue | 13 | 18 | 28 | 35 | 41 | 31 |
| Gross profit | 2 | 5 | 21 | 54 | 99 | 103 |
| Research and development | 22 | 24 | 26 | 29 | 34 | 39 |
| Selling, general and administrative | 15 | 33 | 59 | 75 | 101 | 113 |
| Total operating expenses | 37 | 57 | 85 | 104 | 136 | 151 |
| Operating income | (35) | (53) | (63) | (50) | (37) | (48) |
| Interest expense | 1 | 4 | 5 | 3 | 0 | 0 |
| Interest and investment income | – | 0 | 2 | 7 | 9 | 9 |
| Income before taxes | 28 | (49) | (67) | (49) | (27) | (39) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 28 | (49) | (67) | (49) | (27) | (39) |
| Net income | 28 | (49) | (67) | (49) | (27) | (39) |
| Net income to common shareholders | 3 | (49) | – | – | – | – |